Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2011 February;66(1) > Minerva Chirurgica 2011 February;66(1):1-6

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CHIRURGICA

A Journal on Surgery


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,877


eTOC

 

  BARRET’S ESOPHAGUS


Minerva Chirurgica 2011 February;66(1):1-6

language: English

Does antireflux surgery prevent progression of Barrett’s esophagus?

Lord R. V. N.

Department of Upper Gastrointestinal Surgery, St. Vincent’s Gastroesophageal, Cancer Research Laboratory, St. Vincent’s Hospital
University of New South Wales, Sydney, Australia


PDF  


Mechanistic reasoning suggests that since antireflux surgery treats the gastroesophageal reflux that is the major known risk factor for Barrett’s esophagus, it should have a beneficial effect on the biology of Barrett’s disease. Due to a lack of adequate data, whether this is the case remains uncertain. Most studies, including several large population-based cohort studies, are observational studies that are subject to bias. Selection bias could be present, for example, if the patients undergoing one treatment had worse disease than those undergoing the comparator treatment, which seems possible for antireflux surgery and acid suppression medication therapy. A systematic review also suggests publication bias. The published data indicate that surgeons should not claim that antireflux surgery prevents the progression of Barrett’s. Well-conducted prospective studies with postoperative pH studies suggest, however, that effective surgery may reduce the risk of Barrett’s progression whereas ineffective surgery provides no benefit.

top of page

Publication History

Cite this article as

Corresponding author e-mail

rvlord@stvincents.com.au